Mersana Therapeutics (MRSN) Financials

$29.08

$0.00 (0.00%)

As on 06-Jan-2026 09:30EDT

Market cap

$145 Mln

Revenue (TTM)

$33 Mln

P/E Ratio

--

P/B Ratio

32

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Operating Revenue	33.18	40.50	36.86	26.58	0.04	0.83
Cost of Revenue	0.69	1.63	148.27	0.93	132.01	67.04
Gross Profit	32.89	40.50	36.86	26.58	0.04	-66.21
Operating Expenses	100.27	113.83	207.81	230.35	168.90	88.94
Operating Profit (EBIT)	-67.38	-73.34	-170.96	-203.77	-168.86	-155.15
Other Income	--	--	--	--	0.07	0.42
Profit before Tax	-70.08	-68.77	-171.67	-204.21	-170.06	-88.05
Provision for Tax	-1.22	0.42	1.35	3.33	-0.86	0.36
Profit after Tax (Net Income)	-70.08	-69.19	-171.67	-204.21	-170.06	-88.05
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	-204.21	-170.06	-88.05

Liabilities ($ Mln)	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Shareholder's Funds	-59.54	-9.51	36.90	92.06	121.74	228.09
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	78.95	91.71	125.52	150.75	36.85	15.31
Current Liabilities	43.27	62.46	63.64	91.53	47.52	30.00
Total Liabilities	105.96	144.66	226.06	334.34	206.11	273.40

Assets ($ Mln)	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Non-Current Assets	2.70	7.76	12.00	15.12	17.21	14.82
Current Assets	59.99	136.90	214.06	319.22	188.90	258.58
Total Assets	105.96	144.66	226.06	334.34	206.11	273.40
Total Debt*	2.29	28.60	33.83	36.30	38.18	16.67
Net Current Assets	16.72	74.45	150.42	227.69	141.38	228.58

Cashflow ($ Mln)	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Cash From Operating Activities	--	-82.34	-168.88	-49.36	-139.99	-74.70
Cash Flow from Investing Activities	--	11.44	119.88	-152.72	-0.65	37.03
Cash from Financing Activities	--	4.09	94.68	153.02	63.65	230.41
Net Cash Inflow / Outflow	--	--	--	--	-76.99	192.74

Financials Ratios	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Adjusted EPS ($)	-14.09	-14.00	-35.58	-50.54	-59.11	-32.17
Cash EPS ($)	--	-13.67	-35.30	-50.31	-58.82	-31.80
Adjusted Book Value ($)	--	--	7.65	22.78	42.32	83.34
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-16.66	-35.00	-12.22	-48.66	-27.29
Free Cash Flow per Share ($)	--	-16.69	-35.45	-12.76	-48.88	-27.47

Profitability Ratios	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
ROCE (%)	--	-154.06	-172.45	-141.68	-84.05	-53.23
ROE (%)	--	-505.14	-266.24	-191.03	-97.22	-57.47
ROA (%)	-40.77	-37.33	-61.27	-75.57	-70.93	-46.23
EBIT Margin (%)	-202.94	-160.26	-454.75	-755.74	-392,541.86	-10,641.30
Net Margin (%)	-211.21	-170.86	-465.80	-768.26	-157,462.96	-7,032.35
Cash Profit Margin (%)	0.00	--	--	--	--	--

Growth Ratios	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Revenue Growth (%)	-4.76	0.10	0.39	617.16	-0.95	-0.98
EBIT Growth (%)	4.06	61.28	16.57	-19.01	-91.57	-214.97
Net Profit Growth (%)	6.08	59.69	15.94	-20.08	-93.15	-212.13
EPS Growth (%)	8.07	0.61	0.30	0.15	-0.84	-1.18
Book Value Growth (%)	-5,686.95	--	--	--	--	--

Valuation Ratios	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Price / Earnings	--	-0.10	-0.07	-0.12	-0.11	-0.83
Price / Book Value	32.03	-0.74	0.30	0.26	0.15	0.32
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-2.20	1.56	0.99	1.10	0.73	1.90
Close Price ($)	7.76	35.75	58.00	146.50	155.50	665.25
High Price ($)	70.75	157.00	240.50	208.45	681.92	727.25
Low Price ($)	5.21	30.50	20.04	67.00	121.00	103.00
Market Cap ($ Cr)	145.36	--	--	--	--	--

Solvency Ratios	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Debt to Equity	--	-3.01	0.92	0.39	0.31	0.07
Short term debt to equity ratio	-0.04	-1.72	0.15	0.03	0.02	0.01
Current Ratio	1.39	2.19	3.36	3.49	3.97	8.62
Quick Ratio	1.39	--	--	--	--	--
Interest Coverage	-24.52	-16.75	-41.15	-60.36	-133.22	-245.43

Operating Efficiency Ratios	TTM	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Debtors to sales (%)	0.51	--	--	112.86	--	--
Asset Turnover	0.19	0.22	0.13	0.10	0.00	0.00
Receivable days	--	--	148.66	206.12	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	1,306.76	26.20	5,175.75	28.58	42.60
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.